Prostate Cancer
Sequencing of Sipuleucel-T and ADT for Non-metastatic Prostate Cancer
A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy
Investigator: Evan Ya-Wen Yu, MD; Conditions: Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma; Status: Recruiting; Study ID: NCT01431391
An Open-Label, Phase 1/2, Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Patients With Progressive Advanced Castration-Resistant Prostate Cancer
Investigator: Celestia S. Higano, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01171898
Canary Prostate Active Surveillance Study
Investigator: Daniel W. Lin, MD; Conditions: Prostatic Neoplasms; Status: Recruiting; Study ID: NCT00756665
A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy with Maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer
Investigator: Tia Higano, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT00488982
A Randomized Phase II Study of Combined Androgen Deprivation Versus Combined Androgen Deprivation with IMC-A12 for Patients with New Hormone Sensitive Metastatic Prostate Cancer
Investigator: Evan Yu, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01120236
Phase 2 Trial of Radiation with Androgen Deprivation (RAD): Abiraterone Acetate, Prednisone and LHRH Agonist Prior to and Concurrent with Radiation Therapy.
Investigator: Robert Montgomery, MD; Conditions: Prostate Cancer, Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer; Status: Recruiting; Study ID: NCT01023061
Join Us On